Sarcoma News and Research

RSS

Src can be most promising targets for cancer therapy

Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

6 Apr 2010

Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

5 Apr 2010

Agent Orange exposure: VA adds three new illnesses to list of health problems

Well over 100,000 Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to qualify for disability pay under a proposed regulation published by the Department of Veterans Affairs (VA) that adds three new illnesses to the list of health problems found to be related to Agent Orange and other herbicide exposures.

27 Mar 2010

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.

18 Mar 2010

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).

12 Mar 2010

Fewer injections to treat neutropenia in childhood cancer patients

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

11 Mar 2010

Well-characterized molecular alterations of sarcomas make them ideal models for developing new therapies

New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors.

9 Mar 2010

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

Helicos BioSciences and it’s collaborators will deliver presentations featured at the Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida, from February 24-27, 2010.

26 Feb 2010

ESMO conference on sarcoma and gastrointestinal stromal tumour

More should be done across Europe to ensure that people with rare forms of cancer are not denied access to the best possible treatment, say the organizers of a major European cancer conference to be held in Milan on 9 and 10 March 2010.

25 Feb 2010

Ovarian transplant: A viable method for fertility treatment

For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.

25 Feb 2010

ESMO Conference to address issues relating to sarcoma and GIST

25 Feb 2010

Frozen/thawed ovarian tissue transplant: Woman has two children from separate pregnancies

24 Feb 2010

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

When head and neck tumors - from sinus tumors to acoustic neuromas attached to the hearing and balance nerve at the base of the skull - are located in close proximity to such sensitive areas such as the brain and eyes, they are particularly dangerous due to possible brain injury, visionary risk or hearing loss.

23 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

ALSF commemorates "a decade of standing for hope" by holding high profile lemonade stands

Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) is commemorating "a decade of standing for hope" by holding a string of high profile lemonade stands, the first taking place at the Pro Bowl and Super Bowl. 2010 marks 10 years since cancer patient Alexandra "Alex" Scott (1996-2004) held her first front yard lemonade stand to find a cure for childhood cancer.

11 Feb 2010

Italian researchers identify a new therapeutic approach for Ewing sarcoma

Ewing sarcoma (EWS) is a bone tumor of unknown cellular origin that affects children and young adults. The protein CD99 is highly expressed in most cases of EWS, but its function in the disease is unknown.

9 Feb 2010

News article on the evolving role of hyperthermia in cancer therapy

BSD Medical Corp. reports publication of a news article by the Journal of the National Cancer Institute on the evolving role of hyperthermia in cancer therapy titled, “International Study of Hyperthermia Spurs Hope in U.S.” (J. Natl. Cancer Inst. 2010 102: 79-81; doi:10.1093/jnci/djp530).

3 Feb 2010

Children with cancer are treated with proton therapy at ProCure Proton Therapy Center

Children with cancer are now being accepted for treatment at the ProCure Proton Therapy Center in Oklahoma, where a wide range of tumors are treated with proton therapy, an alternative to X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

28 Jan 2010

ZIOPHARM receives Notice of Allowance for palifosfamide from U.S. patent office

ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled “Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents” with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company’s proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.

27 Jan 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced its plans for 2010 aimed at advancing the clinical development of its high-value drug development pipeline and enhancing shareholder value.

22 Jan 2010

Sarcoma News and Research

Src can be most promising targets for cancer therapy

Rebirth of the cursed drug Thalidomide

Agent Orange exposure: VA adds three new illnesses to list of health problems

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Fewer injections to treat neutropenia in childhood cancer patients

Well-characterized molecular alterations of sarcomas make them ideal models for developing new therapies

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

ESMO conference on sarcoma and gastrointestinal stromal tumour

Ovarian transplant: A viable method for fertility treatment

ESMO Conference to address issues relating to sarcoma and GIST

Frozen/thawed ovarian tissue transplant: Woman has two children from separate pregnancies

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

Second-quarter fiscal 2010 results announced by Pharmacyclics

ALSF commemorates "a decade of standing for hope" by holding high profile lemonade stands

Italian researchers identify a new therapeutic approach for Ewing sarcoma

News article on the evolving role of hyperthermia in cancer therapy

Children with cancer are treated with proton therapy at ProCure Proton Therapy Center

ZIOPHARM receives Notice of Allowance for palifosfamide from U.S. patent office

CytRx announces its plans to advance multiple oncology development programs in 2010

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News